We sought to determine whether continuing medical education (CME) changes real world selection of preventative migraine therapies (anti-calcitonin gene-receptor peptide receptor (CGRP) monoclonal antibodies (mABs)) as measured by prescription and medical claims data.

The CME consisted of 2 expert, online, case-based discussions. Physicians had to complete both, be in the top 5 deciles for migraine claims, and have complete claims 6 months pre-post-CME to be included for the evaluation. 42 primary care and neurology physicians met inclusion criteria, and they were case matched with 42 non-participating physicians using volume of patients with migraine, total prescriptions for oral preventative migraine therapy, profession, specialty, and geography. Participation took place from February to August 2021. Chi-square tests at the physician level and general linear modeling was utilized to examine change in proportion of patients who received anti-CGRP mABs from pre to post for CME vs. comparison groups (P < .05 indicated statistical significance).

• Significantly more physicians in the CME group increased their selection of anti-CGRP mABs for patients with migraine (17% for CME vs. 0% for comparison group; P < .05).
• 40% more patients with migraine received preventive therapy after their clinician participated in both programs 6 months after participation. Controlling for patient volume and prior use of preventive therapy, the CME group had a significantly larger change from pre to post in proportion of patients on preventive migraine therapy (P < .05). Participation in both programs predicted 42% of the variance in change in practice.

This study demonstrates that participation in 2 online CME activities (.50 credits each) can have a positive effect on both neurologists and PCPs, resulting in significant improvements in treatment selection for patients with migraine.